Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) EPS (Basic): ¥-0.16 (TTM As of Dec. 2025)


SHSE:688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
69 GF Score
Price ¥6.92
GF Value ¥6.50
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS (Basic)?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co SHSE:688505 -4.16% 69 EPS (Basic) is ¥-0.16 as of Dec. 2025. GuruFocus rates SHSE:688505 with a GF Score™ of 69/100 and a GF Value™ of ¥6.50 (Fairly Valued). The stock has 2 warning signs investors should review.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was ¥-0.13. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥-0.16.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Diluted) for the three months ended in Dec. 2025 was ¥-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥-0.16.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS without NRI for the three months ended in Dec. 2025 was ¥-0.12. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.14.

During the past 12 months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's average EPS without NRIGrowth Rate was -1790.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 43.30% per year. The lowest was -62.50% per year. And the median was 8.50% per year.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS (Basic) Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS (Basic) Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.13 0.11 0.04 -0.15

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.04 0.00 -0.03 -0.13
SHSE:688505
69GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-157.439-0)/1036.572
=-0.15

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-141.502-0)/1036.572
=-0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ¥-0.16 mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a EPS (Basic) of ¥-0.16 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Basic) too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current EPS (Basic) is ¥-0.16. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Basic) compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EPS (Basic) of ¥-0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current EPS (Basic) is ¥-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Fairly Valued. The stock's GF Value™ is ¥6.50, compared to a current price of ¥6.92 — trading 6.5% above its estimated fair value. The current EPS (Basic) is ¥-0.16. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current EPS (Basic) is ¥-0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥6.92 is trading 6.5% above its estimated GF Value™ of ¥6.50. GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:688505:

  • EPS (Basic): ¥-0.16
  • GF Value™: ¥6.50 vs. price of ¥6.92 (6.5% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
69GF Score

Get the complete analysis for SHSE:688505

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.92
Price
¥6.50
GF Value